title: Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study.
abstract: OBJECTIVE
  To explore the relationship between laser burn intensity and the subsequent risk for development of choroidal neovascularization (CNV) in eyes assigned to the treatment group of the Fellow Eye Study (FES) of the Choroidal Neovascularization Prevention Trial (CNVPT), using computerized methods for laser burn quantitation, and to examine the association between laser burn intensity and (1) drusen reduction and (2) visual acuity.
  
  
  METHODS
  Color fundus images before and immediately after laser treatment in the CNVPT FES were available for 53 of 59 eyes. Prelaser and postlaser treatment images were analyzed using custom-developed computer software, allowing for laser burn identification and quantitation. As measures of laser burn intensity, we derived integrated burn rating (IBR) (the integral of the normalized intensity difference divided by the burn pixels), and the maximum burn intensity (MAX). We identified CNV using fluorescein angiography. A Cox proportional hazards model was fit to the time to development of CNV. Baseline and 6-month color photographs were used to determine reduction in drusen. Visual acuity was measured using a standardized protocol.
  
  
  RESULTS
  The IBR and MAX spanned 4.5 logarithm units. After adjusting for smoking history and predominant drusen size, the risk ratio for CNV per logarithm unit of increasing laser burn intensity for each measure was 2.0 (P =.05) for MAX and 1.7 (P =.07) for IBR. When patients were divided into high- and low-intensity treatment groups of equal size, the high-intensity group had more drusen reduction (57% vs 32%; P =.14). There was no effect of laser intensity on change in visual acuity at 6 months.
  
  
  CONCLUSIONS
  Higher-intensity prophylactic laser applications appear to be associated with a greater risk for development of CNV and with more extensive drusen reduction.
authors.affiliation: Scheie Eye Institute, University of Pennsylvania, 51 N 39th St, Philadelphia, PA 19104, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Kaiser
authors.forename: J W
authors.initials: JW
authors.lastname: Berger
authors.forename: M G
authors.initials: MG
authors.lastname: Maguire
authors.forename: A C
authors.initials: AC
authors.lastname: Ho
authors.forename: N B
authors.initials: NB
authors.lastname: Javornik
mesh_terms: D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000209:etiology*; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects*; D008268:Macular Degeneration / Q000150:complications; D010781:Photography; D016016:Proportional Hazards Models; D015593:Retinal Drusen / Q000601:surgery; D012307:Risk Factors; D013997:Time Factors; D014792:Visual Acuity